Clesrovimab, a long-acting antibody, delivered single-dose protection against RSV lower respiratory tract disease in infants during their first RSV season, according to newly reported performance characteristics tied to the product’s recent US and EU approval. The regimen used a 105 mg dose and was designed for durable protection across the season. For pediatrics and immunization programs, the key operational question is how a one-and-done antibody schedule can fit alongside existing RSV prevention strategies. A single-season durability profile is especially relevant for reducing missed doses and simplifying logistics during the peak respiratory virus window.